Pay in 4 interest-free payments of $7.15 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Mechanism Difference: Tirzepatide (Zepbound/Mounjaro): Dual GIP/GLP-1 receptor agonist Semaglutide (Wegovy/Ozempic): GLP-1 receptor agonist only Published Clinical Trial Data (Separate Studies): Tirzepatide (SURMOUNT-1): 16.0% to 22.5% mean weight loss at 72 weeks depending on dose Semaglutide (STEP trials): Approximately 15% mean weight loss at 68 weeks These trials were conducted separately with different patient populations and protocols
Secondary endpoints included the proportion of participants achieving at least 10, 15, 20, and 25 percent weight loss, change in waist circumference, and improvement in cardiometabolic risk factors such as blood pressure and lipid profiles
GLP-1 therapy is more than a prescription
Compounded semaglutide is worth it for patients who need a more affordable or accessible option, especially when brand-name GLP-1s, such as Wegovy, arent covered by insurance
Who is manufacturing it, and do they provide a Certificate of Analysis
Liposomal Glutathione Readily absorbed and utilised glutathione Liposomes are nano-sized vesicles constructed of a phospholipid bilayer and represent the latest technology in nutrient delivery
